Johnson & Johnson sign at multinational corporation office in Silicon Valley. J&J is headquartered in New Brunswick, New Jersey - Milpitas, CA, USA - October 2019; Shutterstock ID 1524542537; Purchase Order: JnJ

Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the US for All Adults Aged 18 and Older Following CDC and FDA Decision

Originally published at jnj.com. Johnson & Johnson is a DiversityInc Hall of Fame company.

 

On April 23, Johnson & Johnson (the Company) announced that vaccinations with the Company’s COVID-19 single-shot vaccine will resume for all adults aged 18 years and older in the U.S., under Emergency Use Authorization (EUA), following a decision from the United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA).

The decision was based on a recommendation from the U.S. CDC Advisory Committee on Immunization Practices (ACIP), which followed a rigorous evaluation of data relating to a very rare adverse event involving blood clots in combination with low platelet counts (thrombosis with thrombocytopenia) observed within approximately one to two weeks following vaccination.

“As the global pandemic continues to devastate communities around the world, we believe a single-shot, easily transportable COVID-19 vaccine with demonstrated protection against multiple variants can help protect the health and safety of people everywhere. We will collaborate with health authorities around the world to educate healthcare professionals and the public to ensure this very rare event can be identified early and treated effectively,” said Paul Stoffels, Chief Scientific Officer of Johnson & Johnson.

Johnson & Johnson has updated the EUA Fact Sheets for Healthcare Providers Administering Vaccine (Vaccination Providers), and Recipients and Caregivers for the Company’s COVID-19 vaccine, to include information about the diagnosis and treatment of thrombosis with thrombocytopenia. The revised EUA fact sheets is available at: www.janssencovid19vaccine.com.

The CDC, FDA and American Society of Hematology have made information available about the proper recognition and management of this medical condition, and the unique treatment required for this type of blood clot. The health authorities advise that people who have received our COVID-19 vaccine and develop severe headache, chest pain, swelling in the leg, abdominal pain, tiny blood spots under the skin or excessive bruising within two weeks after vaccination should immediately contact their health care provider.

The Company continues to work with other healthcare authorities and regulators around the world to ensure this information is included in product labels for the Company’s COVID-19 vaccine. On April 20, the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) also issued a recommendation, confirming the overall benefit-risk profile of the Company’s COVID-19 vaccine remains positive.

Johnson & Johnson’s COVID-19 Vaccine
The Johnson & Johnson COVID-19 Vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, received EUA from the FDA on February 27, 2021, to prevent COVID-19 in individuals 18 years of age and older.

This decision was based in part on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 66.1 percent effective in preventing moderate to severe/critical disease and 85 percent effective in preventing severe/critical disease across all regions studied, 28 days post-vaccination. The vaccine showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.

The terms of the EUA allow use of the vaccine while more data are gathered. The Company plans to file for a Biologics License Application (BLA) with the FDA later in 2021.

On April 21, 2021, Johnson & Johnson announced the publication of primary data from the Phase 3 ENSEMBLE clinical trial in the New England Journal of MedicineThe primary analysis of the Company’s single-dose COVID-19 vaccine follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints and prevented COVID-19 related hospitalization and death across all study participants 28 days after vaccination. The data also show the vaccine to be consistently effective against symptomatic infection, including in South Africa and Brazil where there was a high prevalence of rapidly emerging SARS-CoV-2 variants.

For more information on the Company’s multi-pronged approach to helping combat the pandemic, visit: www.jnj.com/covid-19.

Latest News

Oak Park, Illinois

Illinois Professor Suspended, Charged with Hate Crime After Allegedly Spitting on Black Woman and Using Racial Slur

An Illinois professor has been suspended from his job and charged with a hate crime after he allegedly spat on and racially attacked a Black female driver in a suburban Chicago grocery store parking lot earlier this month. Antonio Planas of NBC News has reported that Alberto Friedmann, a professor…

Joaquin Castro

New Research Shows a Continued Lack of Hispanic and Latinx Representation in Movies, Media and Publishing

In a bit of disheartening news in the midst of Hispanic Heritage Month, a new government study has confirmed that Latinx individuals are vastly under-included and underrepresented in many parts of the media world. Astrid Galvan of the Associated Press reported on the study from the U.S. Government Accountability Office,…

Newberg, Oregon

Oregon School Employee Suspended for Showing Up to Work in Blackface To Protest State Vaccination Policies

Racial controversies continue to mount at the Newberg Public School system located in the suburbs of Portland, Oregon. Last week, students in the district’s high school conducted a mock “slave auction” on social media in which they ridiculed fellow classmates and discussed how much they would or wouldn’t pay to…